NICE's response to comments on the draft scope and provisional stakeholder list (PDF 207 KB) Published: 24 November 2025
To appraise the clinical and cost effectiveness of Rituximab + Lenalidomide + Epcoritamab within its marketing authorisation for treating follicular lymphoma
This appraisal has been delayed and will now be considered by the NICE Technology Appraisal Committee at a meeting on Tuesday 8 September 2026.